In the latest trading session, 0.48 million Zevra Therapeutics Inc (NASDAQ:ZVRA) shares changed hands as the company’s beta touched 1.93. With the company’s most recent per share price at $6.76 changed hands at -$0.61 or -8.28% at last look, the market valuation stands at $355.71M. ZVRA’s current price is a discount, trading about -24.85% off its 52-week high of $8.44. The share price had its 52-week low at $3.89, which suggests the last value was 42.46% up since then. When we look at Zevra Therapeutics Inc’s average trading volume, we note the 10-day average is 1.93 million shares, with the 3-month average coming to 683.46K.
Analysts gave the Zevra Therapeutics Inc (ZVRA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ZVRA as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Zevra Therapeutics Inc’s EPS for the current quarter is expected to be -0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zevra Therapeutics Inc (NASDAQ:ZVRA) trade information
Instantly ZVRA was in red as seen in intraday trades today. With action -0.73%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 3.21%, with the 5-day performance at -0.73% in the red. However, in the 30-day time frame, Zevra Therapeutics Inc (NASDAQ:ZVRA) is 6.12% up. Looking at the short shares, we see there were 4.4 million shares sold at short interest cover period of 6.24 days.
Zevra Therapeutics Inc (ZVRA) estimates and forecasts
Data shows that the Zevra Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 1.20% over the past 6 months, a -21.54% in annual growth rate that is considerably lower than the industry average of 19.30%. Year-over-year growth is forecast to reach -5.30% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 5.3M. 6 analysts are of the opinion that Zevra Therapeutics Inc’s revenue for the current quarter will be 13.02M. The company’s revenue for the corresponding quarters a year ago was 2.9M and 13.22M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 83.10%. The estimates for the next quarter sales put growth at -1.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 51.89%. The 2024 estimates are for Zevra Therapeutics Inc earnings to decrease by -22.00%.
ZVRA Dividends
Zevra Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Nov-05.
Zevra Therapeutics Inc (NASDAQ:ZVRA)’s Major holders
Among Mutual Funds, the top two as of Jun 30, 2024 were iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. With 1.0 shares estimated at $6.77 million under it, the former controlled 23.18% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 23.09% of the shares, roughly 996.33 shares worth around $6.74 million.
